BTCS Inc
BTCS
DMG BLOCKCHAIN SOLUTIONS INC
DMGGF
Bit Digital
BTBT
TeraWulf
WULF
NEPTUNE DIGITAL ASSETS CORP
NPPTF
US Stock MarketDetailed Quotes
TGTX TG Therapeutics
- 33.880
- +0.490+1.47%
Close Dec 4 16:00 ET
- 33.880
- 0.0000.00%
Post 16:02 ET
5.27BMarket Cap-338800P/E (TTM)
34.330High33.300Low1.71MVolume33.370Open33.390Pre Close57.92MTurnover1.18%Turnover Ratio376.44P/E (Static)155.67MShares36.84052wk High27.46P/B4.94BFloat Cap12.84052wk Low--Dividend TTM145.70MShs Float149414.006Historical High--Div YieldTTM3.09%Amplitude0.956Historical Low33.823Avg Price1Lot Size
TG Therapeutics News
Is TG Therapeutics (NASDAQ:TGTX) Using Too Much Debt?
TG Therapeutics to Participate in the Evercore HealthCONx Conference
JP Morgan Maintains Overweight on TG Therapeutics, Raises Price Target to $43
TG Therapeutics Analyst Ratings
J.P. Morgan Maintains TG Therapeutics(TGTX.US) With Buy Rating, Raises Target Price to $43
Express News | TG Therapeutics Inc : JP Morgan Raises Target Price to $43 From $30
A Closer Look at TG Therapeutics's Options Market Dynamics
TG Therapeutics Ranked Number One on Deloitte Technology Fast 500 for Rapid Growth in Biopharmaceutical Sector
TG Therapeutics Ranked Number One Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500
Reporters Tweets About 'Vague Whispers' of Bid Interest in TG Therapeutics
10 Health Care Stocks Whale Activity In Today's Session
Don't Ignore The Insider Selling In TG Therapeutics
TG Therapeutics | 10-Q: Q3 2024 Earnings Report
Subdued Growth No Barrier To TG Therapeutics, Inc. (NASDAQ:TGTX) With Shares Advancing 27%
TG Therapeutics Call Volume Above Normal and Directionally Bullish
Express News | Goldman Sachs Maintains Neutral on TG Therapeutics, Raises Price Target to $22
A Quick Look at Today's Ratings for TG Therapeutics(TGTX.US), With a Forecast Between $38 to $55
TG Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
TG Therapeutics Boosts Revenue Outlook Amidst Growth
B. Riley Remains a Buyer of TG Therapeutics on Weakness Following Q3 Results